Health TrialsbyHealthPanel

Effect of Sufentanil on the Postoperative Pain

ConditionPostoperative Pain, Acute
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorSeoul National University Hospital

About this trial

This study is a randomized, controlled trial. A total of 48 patients will be randomized to receive sufentanil or remifentanil during robot-assisted nephrectomy surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who undergo elective robot-assisted nephrectomy surgery

American Society of Anesthesiologists grade 1,2,3

Age > 18 years old

Disqualifiers

Refuse to participate to the study

Allergic history of opioid

chronic pain

opioid user before surgery

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sufentanil

    Drug

    Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml

  • Remifentanil

    Drug

    Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml

Treatment groups

48 Participants
are divided into 2 treatment groups
Group A: sufentanil groupExperimental treatment 1 intervention
Group B: remifentanil groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

opioid consumption

Time frame
During post-anesthesia care unit(PACU) stay, until 1 hour

Secondary outcomes

1

Richmond Agitation-Sedation scale

(+4), Combative, Overtly combative or violent; immediate danger to staff (+3), Very agitated, Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff (+2), Agitated, Frequent nonpurposeful movement or patient-ventilator dyssynchrony (+1), Restless, Anxious or apprehensive but movements not aggressive or vigorous 0, Alert and calm, Spontaneously pays attention to caregiver (-1), Drowsy, Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice (-2), Light sedation, Briefly (less than 10 seconds) awakens with eye contact to voice (-3), Moderate sedation, Any movement (but no eye contact) to voice (-4), Deep sedation, No response to voice, but any movement to physical stimulation (-5), Unarousable, No response to voice or physical stimulation

Time frame
During post-anesthesia care unit(PACU) stay, until 1 hour
2

Incidence of postoperative nausea and vomiting

Time frame
During post-anesthesia care unit(PACU) stay, until 1 hour
3

Number of patients who administered antiemetics

ramosetron will be administered as antiemetics

Time frame
During post-anesthesia care unit(PACU) stay, until 1 hour
4

Pain score

Numeric rating scale (0=none, 10=extremely pain)

Time frame
immediately after surgery, 15minutes, 30minutes, 60minutes after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Seoul National University Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: